

CUMULATIVE YEAR-END INDEX—1990

SMALL ANIMAL AUTHOR INDEX

A

Allen, T.A., 909
 Anthony, J., 207
 Appel, M.J.G., 617
 Aron, D.N., 1743

B

Bagley, R.S., 22
 Bahri, L.E., 1414
 Berardi, C., 1557
 Berry, W.L., 141
 Biourge, V., 1244
 Bjorling, D.E., 1699
 Bojrab, M.J., 1541
 Boothe, H.W., 1057
 Boreham, P.F.L., 667
 Boreham, R.E., 667
 Boudrieau, R.J., 341
 Branam, J.E., 1227
 Brown, C.W., 361
 Budsberg, S.C., 1758
 Bukowski, J., 1617
 Burrows, C.F., 1373
 Butt, M.T., 638

C

Campbell, K.L., 543
 Campbell, T.W., 525, 702, 821
 Chandler, M.L., 1601
 Chastain, C.B., 811
 Christie, B.A., 1027, 1035
 Comer, K.M., 13
 Cook, J.R., 31
 Cowell, R.L., 1093
 Crowe, D.T., 55, 1711

D

da Costa, P.D., 1235
 Dean, P.W., 1541
 Dennis, J.E., 1403
 Dow, S.W., 1612
 Dubey, J.P., 653

E

Elkins, A.D., 1589

F

Fettman, M.J., 1612
 Fishback, J.L., 643
 Flanders, J.A., 22
 Fooshee, S.K., 473
 Fossum, T.W., 341
 Freden, G.O., 963
 Frenier, S.L., 1422
 Frenkel, J.K., 643

G

Gavin, P.R., 1422
 Gilson, S.D., 827, 1047
 Goldschmidt, M.H., 783
 Goldstein, G.S., 207, 951
 Guilford, W.G., 313

H

Hall, J.A., 1373
 Harari, J.S., 1557
 Hardy, R.M., 797
 Harris, C.L., 1294
 Hartsfield, S.M., 341
 Hawkins, E.C., 31
 Hedlund, C.S., 1541
 Hill, R.K., 1589
 Hobson, H.P., 341
 Hosgood, G., 45, 1589
 Hoskins, J.D., 1215, 1235, 1579

J

Johnson, E.M., 1093
 Johnston, D.E., 1027, 1035

K

Kemp, D.T., 1758
 King, L., 1244
 Klaue, S.E., 1565
 Klausner, J.S., 797
 Kraft, S.L., 1422
 Krawiec, D.R., 1294
 Kristensen, A.T., 797

L

Latimer, K.S., 55
 Lewis, D.D., 1541
 Lulich, J.P., 59
 Luttgen, P.L., 933, 1077
 Lyon, K.F., 493

M

MacDonald, M.J., 1244
 Maher, E.R., 921
 Mansfield, P.D., 331
 Martin, R.A., 361
 Mautino, M., 221
 Merchant, S.R., 371
 Merchant, S.R., 515
 Miller, W.H., 461
 Moore, M.P., 1422
 Moser, E., 1227
 Mueller, D.L., 157
 Murru, F., 525

N

Noxon, J.O., 157

O

Ogilvie, G.K., 381
 Olson, P.N., 1610
 Osborne, C.A., 59
 Otto, C.M., 55

P

Page, C.D., 221
 Panciera, D.L., 689, 843
 Pavletic, M.M., 1724
 Person, M., 1557
 Petersen, S.W., 1699
 Poffenbarger, E.M., 1601

R

Ralston, S.L., 1601
 Rawlings, C.A., 1272
 Ritchie, B.W., 55
 Roberts, S.M., 1565
 Rochat, M.C., 1093
 Romatowski, J., 183
 Rosin, E., 231
 Ross, L.A., 1277
 Roudebush, P., 909
 Rudd, R.G., 195
 Rudy, R.L., 341
 Rush, J.E., 921

S

Scott-Moncrieff, J.C., 31
 Senior, D.F., 40
 Shell, L.G., 173
 Sherding, R.G., 677
 Speciale, J., 970, 1085
 Stone, E.A., 827, 1047
 Stone, M.S., 963

T

Twedt, D.C., 1373
 Tyler, J.W., 1069, 1260
 Tyler, R.D., 1093

V

Vail, D.M., 381
 Van Pelt, D.R., 1393
 Van Vechten, M., 783

W

Webb, D.M., 1436
 Weiss, D.J., 797
 Wheeler, S.L., 381, 1393
 Whitehair, J.G., 195
 Wingfield, W.E., 1393
 Wise, L.A., 501
 Withrow, S.J., 538
 Wortman, J.A., 783

VOLUME 12 PAGINATION

<i>Issue</i>	<i>Pages</i>	<i>Issue</i>	<i>Pages</i>
January	1-75	July	897-977
February	129-235	August	1017-1103
March	297-387	September	1201-1301
April	449-551	October	1361-1445
May	601-709	November	1521-1629
June	769-859	December	1689-1767

SMALL ANIMAL SUBJECT INDEX

A

Alopecia, symmetrical truncal, in cats, 461-471

allergic disorders, 463
clinical evaluation, 461-462
clinical presentation, 461
diagnostic approach, 470
metabolic disorders, 463-466
miscellaneous disorders, 467
parasitic disorders, 466-467
psychogenic alopecia, 467-470
therapy, 470

Anabolic steroids, 1403-1410

history, 1403
mechanism of action, 1404
structure, 1403-1404
toxicity of anabolic steroids, 1406-1408
use of anabolic steroids, 1404-1406
anemias, 1404-1405
immune-mediated thrombocytopenia, 1405
other uses, 1406
positive nitrogen balance, 1404

Anaphylaxis, 157-170

anaphylaxis not mediated by
immunoglobulin E, 157-159
clinical manifestations, 162-168
anaphylactic shock, 163
anaphylaxis, 162-163
diagnosis, 163-168
immunoglobulin E-mediated anaphylaxis,
157-158
mediators, 159-162
primary mediators, 159-161
secondary mediators, 161-162
treatment, 164, 168-170

Anemia (see also Gastrointestinal neoplasia),
963-966

inflammatory disease, 965-966
iron deficiency, 964-965

Anesthesia (see Anesthetic breathing systems)

Anesthetic breathing systems, for cats and small
dogs, 183-191

cardiopulmonary effects, 184
endotracheal tubes, 185-186
fresh gas flow rates, 187-190
heat loss, 186
respiratory resistance, 184-185
types of anesthetic breathing systems, 183-184
types of semiopen breathing circuits, 186

Antibiotics, selection of, empirical, in small

animal practice, 231-232

Antimicrobial distribution and therapeutics
in bone, 1758-1763

anatomy, 1758

antibiotics commonly used in orthopedics,
1760-1762

aminoglycosides, 1761

β -lactam antibiotics, 1760

cephalosporins, 1761

clindamycin, 1761

fluoroquinolones, 1761-1762

penicillins, 1760-1761

general principles of antibiotic therapy in
orthopedics, 1760

pharmacokinetics, 1758-1759

B

Borreliosis (see Lyme disease)

C

Cancer (see Gastrointestinal neoplasia, Cancer
cachexia, Chemotherapeutic agents, in cats)

Cancer cachexia, metabolic alterations in,
381-386

carbohydrate metabolism, 381-384

insulin action, 384

lipid metabolism, 384

protein metabolism, 382-384

starvation states, 382-384

therapeutic intervention, 385

tumor factors, 384-385

Canine neonatology

cardiopulmonary development, 1603-1604

dentition, 1604

gastrointestinal tract, 1604-1605

hepatic and renal function, 1602

laboratory profiles, 1605-1606

maturation of the immune system, 1606-1607

nonspecific immunity, 1607

passive immunity, 1607

specific immunity, 1606-1607

neurologic development, 1602-1603

cranial nerves and sensory structures, 1603

spinal nerves, 1603

thermoregulation, 1601-1602

Cardiopulmonary resuscitation, use of
bicarbonate in, 1393-1399

SMALL ANIMAL SUBJECT INDEX—CONTINUED

- alternative therapies, 1396-1398
 effects of bicarbonate administration, 1394-1395
 mechanisms of bicarbonate action, 1395-1396
 metabolic abnormalities during cardiac arrest, 1393-1394
 recommendations for therapy, 1398
 Chelonians, see Tortoises
 Chemotherapeutic agents, in cats, 51
 Computers, approach to nutritional management of healthy cats, 473-488
 case presentation, 474
 program results, 474
 canned food, 478
 fish-based foods, 478
 free-choice feeding, 478
 generic brand of food, 478
 obesity, 478-487
 supplementation, 474-478
 Constipation and dyschezia, management of, 677-685
 measures to prevent recurrence of
 constipation, 684
 colectomy, 684-685
 treatment, 682-684
 enema therapy, 684
 manual evacuation of impacted feces, 684
 oral laxative therapy, 682
 emollient laxatives, 682
 high-fiber bulk-forming laxatives, 682
 lubricant laxatives, 682
 osmotic laxatives, 682-684
 stimulant laxatives, 684
 Corticosteroids and aspirin, 1272-1276
 comparison to aspirin controversy in humans, 1276
 historical use and misuse, 1273
 reasons for use, 1273-1274
 recommendations for timing and manner of use, 1272-1273
 responses to typical criticisms, 1274-1276
 Critical care (see Cardiopulmonary resuscitation, use of bicarbonate in, Tube feeding)
 Cytodiagnosis, comparison of avian and mammalian
 effusions, 708
 inflammation of cells, 702-703
 lymphoid tissue, 821-822
 liver, 822
 respiratory tract, 822
 skin and subcutis, 822-824
 malignant neoplasia, 704-705
 tissue hyperplasia or benign neoplasia, 703-704

Dipylidium caninum, dogs and cats, 667-675
 control, 671-674
 chemotherapy, 6671
 hygiene, 671
 vector control, 671-674
 diagnosis, 670-671
 presence of proglottids, 670
 signs in the definitive host, 670-671
 distribution, 667
 human dipylidiasis, 674
 life cycle, 667-670
 adult worm, 667-669
 development in the intermediate host, 669-670
 experimental infections, 670
 infection of the intermediate host, 669
 Distemper, canine, 173-179
 clinical signs, 174-176
 neurologic signs, 174-176
 systemic signs, 174-175
 diagnostic aids, 176-177
 cerebrospinal fluid analysis, 176
 electroencephalography, 176-177
 hematology, 176
 immunofluorescence, 177
 radiography, 176
 serologic testing, 177
 serum chemistries, 176
 epizootiology, 173-174
 pathogenesis, 174
 prevention, 177-178
 treatment and prognosis, 177
 Dyschezia (see Constipation and dyschezia)
 Dystocia in snakes, 361-368
 anatomy, reproduction, and dystocia, 361, 366-367
 clinical cases, 362-367

E
 Electrocardiography, dogs and cats, 811-817
 identifying most normal mean electrical axes, 811-813
 visualizing the location of the mean electrical axis, 813-816
 determining the quadrant, 816-817
 Embryonal rhabdomyosarcoma of the urinary bladder, dogs, 783-793
 case presentation, 783-788
 Emergency treatment (see Cardiopulmonary resuscitation, use of bicarbonate in, Tube feeding)
 Endodontics, basic veterinary, 207-217
 contraindications, 208
 indications, 208-210
 materials and equipment, 212
 signs of dental disease, 207-208
 types of procedures, 208-216
 pulp capping, 209-212
 pulpotomy, 213-216
 pulpotomy, 212-213
 Erythrocyte parasitic diseases, cats, 628-638

D

- Dentistry (see Feline dentistry, Endodontics, Geriatrics, Neonatology)
 Dermatology (see Alopecia, Zoonoses with cutaneous manifestations)

SMALL ANIMAL SUBJECT INDEX—CONTINUED

- cytauxzoonosis, 631-632
- erythrocyte artifacts and inclusions, 632-635
- haemobartonellosis, 630
- methodology, 628-629
- Exotics (see Tortoises, clinical management of, Dystocia in snakes, Fish hematology)

F

- Fecal impaction, cats, 1579-1585
 - causes of fecal impaction, 1580-1581
 - clinical presentation, 1581
 - complications of fecal impaction, 1581
 - pathophysiology of fecal impaction, 1579-1580
 - prevention of fecal impaction, 1581-1582
 - treatment of fecal impaction, 1582-1584
 - enemas, 1583-1584
 - laxatives, 1582-1583
 - surgery, 1584
- Fecal incontinence in cats and dogs, 313-326
 - causes, 315-317
 - cauda equina syndrome, 315
 - central nervous system injury, 315-316
 - colorectal diseases, 315
 - damage to autonomic peripheral nerves, 315
 - damage to muscles of continence, 315
 - damage to somatic peripheral nerves, 315
 - diets that increase fecal volume, 315
 - differential diagnosis and diagnostic tests, 316-321
 - incidence, 313-315
 - reservoir incontinence, 313-314
 - sphincter incontinence, 314-315
 - treatment, 321-322
- Feline dentistry, 493-498
 - acquired disease, 493-494
 - congenital anomaly, 493
 - gingivitis and periodontitis, 494-496
- Feline leukemia (see Immunodiagnosis, in cats)
- Fish hematology, 525-533
 - blood collection, 526
 - clinical piscine hematology, 530-531
 - erythrocytes, 526-527
 - granulocytes, 527-528
 - lymphocytes, 527
 - monocytes, 528-530
 - piscine hematopoietic tissue, 525-526
 - thrombocytes, 530
- Fluid therapy, 55-58
 - intraosseous cannulation in birds, 55-58
 - cannula placement, 56-57
 - evaluation, 57-58
- Fractures (see Patellar fractures, Oblique fractures)

G

- Gastric motility, dogs, 1373-1391
 - diagnosis of disorders, 1373-1375
 - endoscopic and biopsy findings, 1375
 - history and physical examination, 1373

- laboratory findings, 1373-1374
- tests used in evaluation, 1374-1375
- disorders, 1375-1381
 - delayed transit by defective propulsion, 1376-1380
 - delayed transit by obstruction, 1375-1376
 - disorders with accelerated transit, 1380-1381
 - disorders with retrograde transit, 1381
 - disorders of control mechanisms, 1381-1386
 - disorders affecting the fasting state, 1381-1386
 - disorders affecting the fed state, 1386
 - treatment, 1386-1387
- Gastrointestinal neoplasia, primary, anemia in, 13-27
 - case presentations, 13-17
- Geriatrics, canine
 - recommendations for management, 913-916
- cardiovascular changes, 921-931
 - cardiovascular system, 921-928
 - arteriosclerosis, 927-928
 - atherosclerosis, 928
 - cardiac neoplasia, 926-927
 - chronic valvular heart disease, 922-926
 - cor pulmonale, 927
 - management of drug therapy, 928-930
- central nervous system diseases, 933-945
 - caudal cervical vertebral syndrome, 936-941
 - cerebrovascular disease, 945
 - degenerative myelopathy in large dogs, 934-935
 - neoplasia, 941-945
 - brain tumors, 941-943
 - spinal cord tumors, 943-945
 - senile degeneration of the brain, 933-934
 - spondylosis deformans, 935
 - vertebral articular process osteoarthritis, 935-936
- dentistry, 951-961
 - anesthesia, 952
 - clinical signs, 951-952
 - examination, 952
 - oral changes, 953-960
 - ankylosis, 956
 - attrition, 953
 - erosion, 953-954
 - hard tissue changes, 956
 - malignant oral neoplasms, 957-960
 - periodontal disease, 956-957
 - soft tissue changes, 954
 - radiography, 952-953
- diseases of the peripheral nervous system, 1077-1081
 - idiopathic peripheral neuropathies, 1078-1080
 - idiopathic facial nerve paralysis, 1079
 - idiopathic laryngeal paralysis, 1079-1080
 - idiopathic vestibular syndrome, 1078-1079
 - neoplasia, 1080
 - senile deafness, 1077-1078
- nephrology, renal aging, 909-917
 - assessment, 911

SMALL ANIMAL SUBJECT INDEX—CONTINUED

comparative aspects, 909-911
 dietary management, 911-913
 phosphorus, 912-913
 protein, 911-912
 sodium, 913

H

Hematology (see Fish hematology)
 Hepatic disease (see Hepatic lipidosis,
 Hepatoencephalopathy, Liver cytology)
 Hepatic lipidosis, feline, 1244-1258
 case presentations, 1244-1249
 diagnostic studies, 1244-1245
 feeding management, 1245-1249
 history, 1244
 initial examination, 1244
 medical management, 1249
 recovery, 1249
 dietary requirements of cats with liver disease,
 1252-1255
 choice of a diet, 1254
 effects of the diet, 1255
 enteral feeding techniques, 1254-1255
 medical management, 1255
 mineral requirements, 1253
 protein requirements, 1253
 vitamin requirements, 1253-1254
 pathophysiology, 1249-1252
 Hepatoencephalopathy
 diagnosis, 1070-1072
 laboratory evaluation, 1070-1071
 specific liver function tests, 1071-1072
 underlying liver disease, 1072
 pathophysiology, 1260-1264
 abnormalities in neurotransmitter balance,
 receptor densities, and affinities,
 1260-1261
 peripheral toxins and metabolic-endocrine
 derangements that cause or enhance
 hepatoencephalopathy, 1261-1264
 signalment and presenting clinical signs,
 1069-1070
 treatment, 1264-1268
 Hyperbaric oxygen therapy, 1589-1593,
 1597
 complications, 1593
 definition, 1589
 delivery and apparatus, 1589-1590
 historical perspective, 1589
 investigative indications, 1592
 mechanism of effect, 1590-1592
 antimicrobial effects, 1590-1591
 aerobic and facultative anaerobic
 antimicrobial activity, 1591
 anaerobic and microaerophilic bactericidal
 activity, 1591
 antibiotic enhancement, 1591
 detoxification of toxic compounds, 1591
 oxygen-dependent antimicrobial activity,
 1590-1591
 hyperoxygenation, 1590

neovascularization, 1591-1592
 osteoclast stimulation, 1592
 vasoconstriction, 1590
 wound healing enhancement, 1591
 potential clinical indications, 1592
 clostridial infections, 1592
 crush injury, drag injury, and other acute
 traumatic ischemias, 1592
 free skin grafts and flaps, 1592
 refractory osteomyelitis, 1592
 Hypokalemia, cats, 1612-1615
 diagnosis, 1614
 maintenance therapy, 1615
 potassium balance, 1612-1614
 prevalence and disease association, 1614
 treatment, 1614-1615
 Hypothyroidism, canine
 cause, 689-690
 clinical signs, 690-692
 laboratory findings, 692
 signalment, 689
 tests of thyroid function, 843-850
 thyroid hormone metabolism, 696
 thyroid hormone secretion control, 693-694
 thyroid hormone synthesis, 693
 thyroid hormone transport, 694-696
 thyroid physiology, 692-696
 treatment, 850-854

I

Immunodiagnosis, in cats, 501-510
 feline immunodeficiency virus infection, 506
 feline infectious peritonitis, 501
 feline leukemia virus infection, 502
 antibody tests, 506
 discordant test results, 506
 enzyme-linked immunosorbent assay, 503
 indirect fluorescent antibody, 503
 latent infection, 506
 toxoplasmosis, 506-507
 Incontinence (see Fecal incontinence)
 Insecticides, associated health risks, 1617-1626
 botanicals, 1621-1622
 acute toxicity, 1621
 chronic or allergic effects, 1621-1622
 organochlorines, 1621-1622
 organophosphates and carbamates,
 1617-1621
 acute toxicity, 1618
 chronic toxicity, 1618-1621
 immunotoxic effects, 1619-1620
 neurologic effects, 1618-1619
 other effects, 1620-1621
 pyrethroids, 1622
 recommendations, 1622-1623
 Intracranial astrocytomas, canine, comparison
 with human counterpart, 1422-1433
 classification, 1422-1423
 diagnosis, 1423-1426
 prevalence and clinical findings, 1423
 therapy, 1427-1432

SMALL ANIMAL SUBJECT INDEX—CONTINUED

L

- Laparotomy, exploratory, 1057-1067
 - indications, 1057
 - technical considerations, 1058-1065
 - biopsy techniques, 1059
 - intestines, 1060
 - kidneys, 1064
 - liver, 1059-1060
 - lymph nodes, 1060-1064
 - other tissues, 1064-1065
 - prostate gland, 1064
 - equipment needs, 1058
 - exploration of the peritoneal cavity, 1058-1059
 - intraoperative peritoneal lavage, 1065
 - positioning, 1058
 - preparation, 1058
 - surgical approach, 1058
 - therapeutic intervention, 1065
 - wound closure considerations, 1065
 - timing, 1057-1058
- Lasers, use in surgery, 1565-1577
 - history of lasers, 1565
 - laser control, 1566-1567
 - laser physics, 1565-1566
 - laser use in veterinary surgery, 1571-1574
 - anesthetic management, 1575-1576
 - endotracheal tube in the airway, 1575
 - lubrication of the tube, 1575-1576
 - noncombustible endotracheal tubes, 1575
 - protection of the tube's external surface, 1575
 - hazards to the operating team, 1574
 - hazards to the patient, 1574-1575
 - tissue biology, 1567-1568
 - types of lasers, 1568-1571
 - argon laser, 1570-1571
 - carbon dioxide laser, 1569-1570
 - krypton laser, 1571
 - Nd:YAG laser, 1568-1569
 - other lasers, 1571
- Liver cytology in hepatic disease, canine and feline, 797-809
 - interpretation and classification, 798-799
 - cholestatic, 799
 - degenerative, 799
 - hyperplastic, 798
 - inflammatory, 798-799
 - mixed reactions, 799
 - necrotic, 799
 - neoplastic, 799
 - nondiagnostic, 799
 - normal, 798
 - other reactions, 799
 - obtaining and preparing specimens, 797-798
 - retrospective study, 799-804
- Liver disease (see Hepatic lipidosis, Hepatoencephalopathy, Liver cytology)
- Lyme disease, 617-625
 - causative agent, 618
 - diagnosis, 622-623
 - disease signs, 620-622
 - epizootiology, 618-620

- immune response, 622
- prevention and control, 624
- public health aspects, 624
- treatment, 623-624

M

- Muscle disorders, canine, 31-38
 - diagnostic evaluation, 31
 - electromyography and nerve conduction velocity, 32-33
 - muscle biopsy, 32-33
 - physical findings, 31
 - presentation, 31
 - serum muscle enzymes, 31-32
 - muscle disorders, 33-38
 - congenital myopathies, 36
 - dermatomyositis, 36
 - endocrine disorders, 37
 - exertional rhabdomyolysis, 36-37
 - fibrotic myopathy, 37
 - immune-mediated myositis, 33-36
 - infectious myositis, 36
 - myasthenia gravis, 37
 - other disorders, 38
 - paraneoplastic myopathy, 37

N

- Neonatology (see Canine neonatology, Kittens, clinical evaluation of)
- Neoplasia (see Gastrointestinal neoplasia)
- Neospora caninum*, 653-665
 - experimental animal models, 662
 - history, 653
 - host range and distribution, 654
 - life cycle and structure, 653-654
 - neosporosis in cats, 662
 - neosporosis in cattle, 662
 - neosporosis in dogs, 655-662
 - clinical signs, 656-659
 - diagnosis, 659
 - lesions, 659
 - prevalence, 655
 - repeated transplacental transmission, 655-656
 - treatment, 662
 - pathogenesis, 655
 - transmission, 654-655
- Neuroendocrine update, 970-973
 - early discoveries, 970-971
 - discovery of acetylcholine, 970-971
 - discovery of catecholamines and other peptides, 971
 - releasing factors and active compounds, 971-972
 - brain-gut connection, 972
 - brain-heart connection, 972
 - unity, 971
- Neuroendocrinology (see Neuroendocrine update)

SMALL ANIMAL SUBJECT INDEX—CONTINUED

Nutrition (see also Tube feeding)

- feline, 1227-1240
 - taurine, role of, cats, 1235-1240
 - diagnosis, 1239
 - dilated cardiomyopathy, 1238
 - miscellaneous findings, 1238-1239
 - reproductive and developmental abnormalities, 1237
 - retinal lesions, 1235-1237
 - therapy, 1239
 - topical issues, 1227-1232
 - feline hepatic lipidosis, 1229-1230
 - general nutritional considerations, 1227-1228
 - hypokalemic polymyopathy, 1229
 - magnesium and urine acidification, 1229
 - taurine deficiency, 1228-1229
- Nutritional support (see Tube feeding)

O

- Oblique fractures, management of, 1743-1755
 - biomechanics, 1745-1746
 - fracture healing, 1744-1745
 - oblique fractures, 1743-1744
 - techniques, 1746-1754
 - bone plates, 1751-1752
 - external coaptation, 1746-1747
 - external skeletal fixation, 1750-1751
 - external skeletal fixation and cerclage wires, 1754
 - intramedullary pin, 1747-1750
 - lag screws, 1752-1754
- Omentum, surgical applications of, 45-50
 - anatomy, 45
 - blood supply, 45-46
 - histology, 45, 46
 - innervation, 46
 - lymphatic drainage, 46
 - function, 46
 - adhesion, 46
 - angiogenesis, 46
 - fat storage, 46
 - immune function, 46
 - surgical applications, 46
 - abdominal surgery, 48-49
 - bladder reconstruction, 49
 - extraperitoneal anastomosis, 48-49
 - gastrointestinal anastomosis, 48
 - gastrostomy or enterostomy tubes, 49
 - hemostasis, 49
 - revascularization, 49
 - tube gastropexy, 49
 - complications, 49
 - omental graft, 46-49
 - creation, 47
 - exteriorization, 47
 - reconstruction, 48
 - body wall defects, 48
 - other reconstructive procedures, 48
 - protection of vasculature, 48

- thoracic cavity surgery, 49
- Oncologic surgery (see also Surgical oncology patient)
 - principles, 827-839
 - applications of surgery, 827-830
 - diagnosis, 827-828
 - prevention, 827
 - reconstructive surgery, 830
 - staging, 828-829
 - surgery as part of multidisciplinary therapy, 829-830
 - surgical cure, 829
 - surgical palliation, 829
 - surgical treatment of emergencies, 829
 - treatment of complications from other therapies, 829
 - treatment of metastases, 830
 - principles of surgical technique, 830-837
 - planning, 832
 - patient preparation, 832
 - technique, 832-834
 - reasons for failure, 837
- Oncology, veterinary, 538
- Orthopedics (see Antimicrobial distribution)
- Osteochondritis dissecans of the humeral head,
 - in dogs, 195-203
 - causes, 195
 - diagnosis, 196-197
 - anamnesis, 196
 - ancillary diagnostic modalities, 197
 - clinical signs and physical examination, 196
 - differential diagnosis, 197
 - radiography, 196-199
 - signalment, 196
 - pathogenesis, 195-196
 - prognosis, 199-202
 - treatment, 197-199
 - medical management, 198-199
 - surgical management, 199-202
- Ototoxicity, dogs and cats, 331-337
 - anatomy of the inner ear, 331-333
 - drugs in the inner ear, 332-333
 - ototoxic substances, 333-336
 - antibiotics, 333-334
 - antineoplastic agents, 334-336
 - antiseptic compounds, 334
 - diuretics, 334
 - miscellaneous agents, 336
 - physiology of the ear, 332
 - risk factors associated with aminoglycoside therapy, 336
 - therapeutic considerations, 336

P

- Paragonimiasis, dogs and cats, 1093-1100
 - clinical signs and diagnosis, 1094-1096
 - hematology, 1094
 - radiography, 1094-1096
 - serology, 1096

SMALL ANIMAL SUBJECT INDEX—CONTINUED

life cycle, 1094
 pathology, 1096-1098
 taxonomy and host range, 1093-1094
 treatment, 1098
 albendazole, 1098
 febantel, 1098
 fenbendazole, 1098
 praziquantel, 1098

Parasitology (see *Dipylidium caninum*, Erythrocyte parasitic diseases, Lyme disease, *Neospora caninum*, Paragonimiasis, *Toxoplasma oocysts*)

Patellar fractures, 1557-1563
 applied anatomy, 1557
 clinical presentation and diagnosis, 1558
 pathophysiology, 1557-1558
 treatment and prognosis, 1558-1562

Pectus excavatum in dogs and cats, 341-355
 anesthesia, 343-350
 causes, 341-342
 clinical signs, 342-346
 pathophysiology, 342
 postoperative management, 351
 surgery, 350

Poisoning (see Vitamin D₃-containing rodenticide poisoning, Insecticides)

Polycythemia in dogs, 543-550
 diagnosis, 545-548
 normal erythropoiesis, 543-544
 primary polycythemia, 545
 relative polycythemia, 544
 secondary polycythemia, 544
 physiologically appropriate polycythemia, 544-545
 physiologically inappropriate polycythemia, 545
 treatment, 548

Potassium depletion, in cats (see Hypokalemia)

Protein-creatinine ratios, 59-72
 canine, 59-69
 clinical value of, 63-67
 cause of protein-losing glomerulopathy, 64-65
 confirming significant proteinuria, 62-64
 daily urine protein losses, 65-66
 glomerular disease, 64
 monitoring response to therapy, 65-66
 postglomerular disease, 65
 predicting clinical outcome, 67
 conditions associated with proteinuria in dogs, 62
 mechanisms of renal excretion of protein, 60-62
 normal values, 60
 reliability of, 67, 69
 terms related to proteinuria, 61
 when to evaluate, 67-69
 feline, 70

R

Retroperitoneum, dogs, 1027-1045
 anatomic findings, 1028
 anatomic models, 1027-1028

retroperitonitis, 1035-1045
 causes, 1036
 clinical signs, 1036
 treatment and results, 1036-1038

S

Serum sodium concentration disorders, 1277-1289
 hyponatremia, 1278
 causes, 1278
 diagnosis, 1278-1279
 pathophysiology and clinical signs, 1278
 therapy, 1279-1280
 hyponatremia, 1280
 causes, 1280
 diagnosis, 1284-1288
 pathophysiology and clinical signs, 1280
 therapy, 1288
 pathophysiology, 1277-1278

Stapling devices, surgical, 1724-1741
 end-to-end anastomosis staplers, 1729-1737
 description, 1729-1730
 uses, 1730-1732
 gastrointestinal staplers, 1762-1729
 description, 1726
 uses, 1726-1729
 ligating dividing stapler, 1737-1738
 description, 1737-1738
 uses, 1738
 skin and fascia staplers, 1738-1739
 description, 1738-1739
 uses, 1739
 thoracoabdominal staplers, 1724-1726
 description, 1724-1725
 uses, 1725

Steroids (see Anabolic steroids, Corticosteroids)

Suction, 1436-1440
 a suction apparatus, 1437-1440
 suction tips, 1436-1437
 uses of suction, 1436

Surgical devices (see Lasers, Stapling devices, Suction)

Surgical oncology patient, management of, 1047-1051
 long-term monitoring, 1050-1051
 perioperative, 1048-1049
 postoperative, 1049-1050
 preoperative, 1047-1048

T

Tortoises, clinical management of, 221-228
 clinical assessment, 222
 anamnesis, 222
 chemical restraint, 223
 diagnostic procedures, 223
 hematology and serum chemistries, 223-224
 microbiology, 224
 parasitologic examination, 223
 physical examination, 222-223
 radiology, 224
 husbandry, 221-222
 housing and substrate, 221

SMALL ANIMAL SUBJECT INDEX—CONTINUED

- nutrition, 221-222
- temperature, humidity, and lighting, 222
- therapy, 224-227
 - fluid therapy, 224-226
 - nutritional support, 226-227
 - therapeutic agents, 227
- Toxoplasma* oocysts, vaccines to prevent feline shedding, 643-651
- future clinical use, 646-648
- life cycle, 644
- vaccine development, 644-646
- Tube feeding, 1711-1721
 - central total parenteral nutritional (TPN) support, 1719-1720
 - ostomy tube removal, 1717-1718
 - partial parenteral nutritional (PPN) support, 1718-1719
 - role of nutritional support, 1711-1714
 - types of enteral feeding in critical patients, 1714-1717
 - esophagostomy tube, 1714-1716
 - gastroduodenostomy tube, 1716-1717
 - gastrostomy tubes, 1716
 - jejunostomy tube, 1717
 - nasoesophageal and nasogastric tubes, 1714
 - pharyngostomy tube, 1714
- Tumors (see Intracranial astrocytomas)

U

- Uremic bleeding, pathophysiology of, 1294-1299
 - platelet aggregation in uremia, 1295
 - the role of coagulation factors, 1296
 - the role of compounds, 1295-1296
 - the role of eicosonoid synthesis, 1296
- Urethrotomy and urethrostomy, canine, 1541-1555
 - anatomy, 1541
 - females, 1542
 - males, 1541-1542
 - preoperative considerations, 1542-1543
 - urethrostomy techniques, 1547-1553
 - perineal, 1548-1549
 - postoperative management, 1553
 - prepubic, 1549-1553
 - prescrotal, 1547-1548
 - scrotal, 1548
 - urethrotomy techniques, 1543-1547
 - closure considerations, 1545-1546
 - perineal, 1548-1552
 - postoperative management, 1546-1547
 - prescrotal, 1544-1545
 - urinary continence, 1542
 - urinary tract infection, 1542
- Urinary tract diversion, surgical techniques of, 1699-1709
 - bladder, 1701-1706
 - tube cystostomy and cutaneous urinary diversion, 1701-1702
 - urinary diversion into the gastrointestinal tract, 1706
 - urinary diversion via isolated bowel conduit or reservoir, 1702-1704

- kidneys, 1699-1709
 - injuries of the renal vasculature, 1700-1701
 - lesions of the proximal ureter, 1700
 - nephropylotomy, 1700
 - partial nephrectomy, 1700
- ureters, 1701
 - treatment of a shortened ureter, 1701
- ureteral replacement, 1701
- urethra, 1706-1707
 - extrapelvic anastomosis, 1707
 - urethrostomy, 1707
- Urinary tract, lower, feline disease of, 40-43
 - causes of inflammation, 40-41
 - crystal growth and dissolution, 42
 - diet formulation, 42-43

V

- Vascular access systems, totally implantable, 22-27
 - additional clinical implications, 1086
 - clinical implications of peptide physiology, 1085-1086
 - angiotensin, 1085
 - cholecystokinin, 1086
 - clinical use, 26
 - implantation, 23-24
 - maintenance, 24-26
 - modern theories, 972-973
 - APUD theory, 972-973
 - Unification theory, 973
 - subcutaneous drug delivery depot, 22-23
 - therapeutic applications, 1086-1088
 - atrioheptins, 1088
 - dynorphin, 1086
 - naloxone hydrochloride, 1086-1087
 - thyrotropin-releasing hormone, 1087
- Vitamin D₃-containing rodenticide poisoning, dogs, 1414-1419
 - chemistry, 1414
 - clinical signs, 1416
 - diagnosis, 1417
 - lesions, 1416-1417
 - mechanism of action, 1415-1416
 - pharmacokinetics, 1414-1415
 - source, 1414
 - toxicity, 1414
 - treatment, 1417
 - specific, 1417
 - symptomatic, 1417

W

- Weakness, episodic, in dogs, 141-153
 - cardiorespiratory disorders, 152
 - metabolic disorders, 147-152
 - hypercalcemia, 151
 - hypoadrenocorticism, 147
 - hypoglycemia, 147
 - hypokalemia, 150-151
 - hypothyroidism, 151-152
 - myopathic disorders, 141-144
 - congenital myotonia, 141

SMALL ANIMAL SUBJECT INDEX—CONTINUED

dermatomyositis in collies, 142-143
 episodic collapse in King Charles spaniels,
 143
 hereditary myopathy in Labrador retrievers,
 141-142
 hyperadrenocortical myopathy, 144
 polymyositis, 143-144
 neuromuscular and neurologic disorders,
 144-147
 myasthenia gravis, 144-146
 narcolepsy, 146
 scottie cramp, 146

Z

Zoonoses with cutaneous manifestations

Cheyletiella infestation, 372
 clinical features, 372-373
 clinical management, 373
 diagnosis, 373
 epidemiology, 372
 general information, 372
 dermatophytosis, 516
 clinical features, 517
 dogs and cats, 517
 humans, 517-518
 clinical management, 518-520
 diagnosis, 518

epidemiology, 516-517
 general information, 516
 feline scabies, 375
 clinical features, 375
 clinical management, 375
 diagnosis, 375
 general information, 375
 flea allergy dermatitis, 371-372
 clinical features, 371-373
 clinical management, 372
 diagnosis, 372
 general information, 371
 sarcoptic mange, 373-375
 clinical features, 374-375
 clinical management, 375
 diagnosis, 375
 epidemiology, 374
 general information, 373-374
 sporotrichosis, 515
 clinical features, 516
 dogs and cats, 516
 humans, 516
 clinical management, 516
 diagnosis, 516
 epidemiology, 515-516
 general information, 515

EQUINE AUTHOR INDEX

A

Allen, A.K., 1307
 Asbury, A.C., 1477
 Austin, S.M., 1110

B

Baker, G.J., 1110
 Bertone, A.L., 262
 Blanchard, T.L., 563
 Bramlage, L. R., 1783
 Bretzlaff, K.N., 563
 Brewer, B.D., 415, 1773
 Buergelt, C.D., 872

C

Cash, W.C., 1120
 Clem, M.F., 862, 1120, 1633
 Cohen, D., 1449
 Cohen, N.D., 1449
 Collatos, C., 393
 Cox, J.H., 83, 91
 Coyne, C.P., 91

D

DeBowes, R.M., 83, 91, 862, 1120
 DiPietro, J.A., 713, 1110
 Dubielzig, R.R., 1643

E

Elmore, R.G., 563

F

Foil, C.S., 723
 Foil, L.D., 723
 Foreman, J.H., 1110
 French, D.D., 713

G

Gatewood, D.M., 1120
 Gaughan, E.M., 1633
 Geor, R.J., 403

H

Hance, S.R., 862
 Herd, R.P., 732
 Hintz, H.F., 78

K

Kiper, M.L., 993
 Klei, T.R., 713
 Koterba, A.M., 1773

L

Lombard, C.W., 872
 Lust, G., 980

M

Mansmann, R.A., 251
 Martin, M.T., 563
 McClure, J.J., 262
 Modransky, P., 1633

N

Nixon, A.J., 1463

P

Papich, M.G., 403
 Paradis, 1650
 Pearson, E.G., 555

R

Rashmir-Raven, A., 1120, 1633
 Reed, S.M., 1107
 Reef, V.B., 1312
 Reimer, J.M., 1321
 Robertson, J.T., 1107

S

Schneider, R.K., 1783
 Schott, H.C., 251
 Scrutchfield, W.L., 563
 Smith, B.P., 1459
 Spurlock, G.H., 241
 Spurlock, S.L., 241
 Stone, L.R., 1307
 Stone, W.C., 1643

EQUINE AUTHOR INDEX—CONTINUED

T

Taylor, T.S., 563
 Todd, K.S., 1110
 Todhunter, R.J., 980
 Traub-Dargatz, J.L., 993

V

Varner, D.D., 563

W

Welch, R.D., 862
 Whitehair, K.J., 91
 Wilson, D.G., 1643
 Wilson, J.H., 872
 Wrigley, R.H., 993

VOLUME 12 PAGINATION

<i>Issue</i>	<i>Pages</i>	<i>Issue</i>	<i>Pages</i>
January	76-97	July	978-1001
February	236-265	August	1104-1127
March	388-419	September	1302-1327
April	552-571	October	1446-1485
May	710-737	November	1630-1657
June	860-877	December	1768-1791

EQUINE SUBJECT INDEX

A

Albumin deficiency (see Hypoalbuminemia)
 Arthritis (see Synovitis)
 Arthropod pests, 723-731
 acarines, 728-730
 chiggers and pyemotid mites, 728
 follicle mites, 729
 mange mites, 729
 ticks, 729-730
 blister beetles, 728
 cutaneous conditions, 730
 habronemiasis, 730
 onchocerciasis, 730
 flies, 723-728
 biting midges, 724-725
 blackflies, 724
 cattle grubs, 728
 horn flies, 725
 horse botflies, 726
 houseflies, stable flies, and face flies,
 725-726
 mosquitoes, 727-728
 myiasis, 727
 tabanids, 723-724
 lice, 728
 sticktight fleas, 728

B

Bacterial isolates in intensive care, 1773-1781
 materials and methods, 1775
 results, 1775
 antibiotic susceptibility patterns, 1776
 bacterial isolates, 1775
 predominant sites of infection, 1776
 Borreliosis, 1449-1458
 agent, 1449-1450

clinical signs, 1451-1452
 diagnosis, 1452-1453
 epidemiology, 1450-1451
 treatment, 1453-1458

C

Calcinosis circumscripta, 1643-1649
 Cardiology (see Pericarditis, Pulmonary disease)
 Catheters, complications of, 241-245
 catheter selection, 245
 contamination factors, 242, 244
 guidelines for minimizing complications,
 244-245
 insertion, 245
 insertion technique, 243, 244
 maintenance, 245
 materials, 244
 patient-related factors, 241
 sepsis, 242
 thromboembolism, 241
 thrombophlebitis, 241
 Cervical vertebral stenotic myelopathy,
 treatment of, 1107-1109
 Cyathostomes and *Strongylus vulgaris*, 732-736
 integrated parasite control, 734
 larval cyathostomiasis, 733
 problems in treating larval cyathostomiasis,
 733
 Strongylus vulgaris in arteries, 733-734

D

Dentigerous cysts, 1120-1127
 clinical presentation, 1120-1121
 complications, 1123
 diagnostic procedures, 1121

EQUINE SUBJECT INDEX—CONTINUED

preoperative considerations, 1122
 prognosis, 1123
 surgical anatomy, 1122-1123
 surgical procedure, 1123
 Dentistry (see Dentigerous cysts)
 Dermatology (see Sarcoids)
 Drainage, thoracic, 251-261
 management of pleural effusion, 253-260
 indwelling chest tube drainage, 254-256
 intermittent chest tube drainage, 253-254
 open thoracic drainage, 258-260
 thoracic lavage, 256-257
 pleural fluid analysis, 253, 254
 thoracocentesis, 251-253
 Dystocia, 563-571
 metritis and laminitis, 564-565
 periparturient events that lead to Stage 3,
 563-564
 retained placenta, 564
 treatment, 565-566
 metritis and laminitis, 566-568
 retained placenta, 565-566

E Echocardiography (see Ultrasonography)
 Endometritis and acute metritis, management of
 using large-volume uterine lavage, 1477-1479
 clinical applications, 1478-1479
 active endometritis, 1478-1479
 acute metritis, 1479
 lavage for normal foaling mares, 1479
 recurrent endometritis, 1479
 techniques, 1478
 cycling mares, 1478
 postpartum mares, 1478
 Esophageal obstruction, 91-96
 clinical signs and physical examination, 91-92
 conservative management, 94-95
 diagnostic evaluation, 92-94
 history, 91
 medical therapy, 95
 patient reevaluation, 95
 prevention, 95

F Fistulous withers, 1633-1641
 diagnosis, 1635
 human health hazard, 1634-1635
 idiopathic form, 1633-1634
 medical therapy, 1635-1637
 other infectious causes, 1635
 prognosis, 1640
 surgical anatomy, 1637
 surgical therapy, 1637-1640
 traumatic form, 1634

G Gastrointestinal ulceration, in foals, medical
 therapy for, 403-412
 mucosal defense mechanisms, 403-405
 effects of nonsteroidal antiinflammatory
 drugs, 405
 epithelial cell restitution, 404
 mucosal blood flow, 404
 mucus-bicarbonate barrier, 403-404

prostaglandins and mucosal protection,
 404-405
 pathophysiology of ulcer formation, 405-406
 therapy, 406-410
 antacid drugs, 406-407
 anticholinergics, 410
 cytoprotective drugs, 408-410
 licorice products, 410
 synthetic prostaglandins, 408-410
 histamine H₂-receptor antagonists, 407-408
 adverse effects and drug interactions,
 407-408
 cimetidine and ranitidine, 407
 omeprazole, 408
 other therapeutic considerations, 410
 sucralfate, 408

H Hernias, 862-871
 inguinal, 864-867
 acquired, 865-866
 congenital, 864-865
 treatment, 866
 umbilical, 862-864
 diagnosis, 862-863
 strangulated and hernias, 864
 treatment, 863-864
 ventral, 867-870
 diagnosis, 867
 treatment, 867-870
 Hyperkalemic periodic paralysis (see Weakness)
 Hypoalbuminemia, 555-559
 diagnostic plan, 558-559
 failure to produce albumin, 557
 increased metabolism of albumin, 557
 loss of albumin, 556
 normal albumin metabolism, 555-556
 relative prevalence of hypoalbuminemia,
 557-558
 sequestering of albumin outside the
 vasculature, 556-557

I Intensive care (see Bacterial isolates in intensive
 care)

L Lyme disease (see Borreliosis)

N Neonatal intensive care, success or failure?,
 413-418
 Neonatology (see Gastrointestinal ulceration, in
 foals, Neonatal intensive care, Seizures
 in foals)
 Nerve injury (see Cervical vertebral stenotic
 myelopathy, Suprascapular nerve injury)
 Nutrition, 78-81, 89
 alfalfa, 80
 fat mares, 78-80
 linseed meal, 78
 processing of oats, 80
 trace mineralized salt, 80-81

EQUINE SUBJECT INDEX—CONTINUED

O

- Orthopedics (see Osteochondrosis and osteochondritis dissecans, Synovitis)
 Osteochondrosis and osteochondritis dissecans, 1463-1475
 dorsal sagittal ridge osteochondrosis, 1464-1466
 diagnosis, 1464-1465
 treatment, 1465-1466
 first phalanx subchondral cystic lesions, 1469-1472
 diagnosis, 1469
 treatment, 1469-1472
 metacarpal subchondral cystic lesions, 1466-1469
 diagnosis, 1466-1467
 treatment, 1467-1469
 palmar condylar osteochondritis dissecans, 1464
 diagnosis, 1464
 treatment, 1464
 pathogenesis, 1463-1464
 plantar or palmar first phalanx osteochondrosis, 1472-1473
 diagnosis, 1472
 treatment, 1473

P

- Parascaris equorum* infections, 1110-1119
 control, 1112-1115
 chemotherapy, 1112-1114
 avermectins, 1113-1114
 benzimidazoles, 1112
 failure of anthelmintic treatments, 1114
 imidazothiazoles, 1112
 organophosphates, 1113
 phenylguanidines, 1113
 simple heterocyclics, 1112
 tetrahydropyrimidines, 1112
 environmental control, 1115
 prevention, 1114
 disease development, 1111-1112
 clinical signs, 1111
 immunity to infection, 1112
 pathogenesis, 1111-1112
 life cycle, 1110-1111
 development of the infective stage, 1110
 larval migration, 1110
 patency, 1110-1111
 transmission, 1111
 Parasitology (see also Arthropod pests, Borreliosis, Cyathostomes, and *Strongylus vulgaris*, *Parascaris equorum* infections, Salmonellosis)
 contemporary topics, 713-721
 parasites and diarrhea, 714-716
 pathogenicity and relevance of strongyles, 713-714
 tapeworms, 716-718
 anthelmintic programs and rotation, 718-720
 efficacy and safety of ivermectin in foals, 718
 Pericarditis, 872-877
 analysis of pericardial fluid, 874

- clinical laboratory findings, 873
 clinical signs, 873
 diagnostic methods, 873-874
 differential diagnosis, 874-875
 effusive, 872
 fibrinous, 872-873
 morphologic findings, 875
 treatment and prognosis, 875-876
 types and causes, 872
 Pulmonary disease, chronic obstructive, 1650-1653
 clinical signs, 1650-1651
 pathogenesis, 1651-1652
 treatment, 1652

R

- Renal ultrasonography (see Ultrasonography)

S

- Salmonellosis, 1459-1461
 Sarcoids, therapy for, 262-265
 physical therapy, 263-264
 autogenous vaccines, 263
 chemotherapy, 263
 cryotherapy, 263
 hyperthermia, 263
 immunotherapy, 263
 laser therapy, 263
 mycobacterial products, 263
 radiotherapy, 263
 surgery, 263
 Seizures in foals, 393-399
 causes, 394-396
 bacterial meningitis, 395
 idiopathic epilepsy, 396
 neonatal maladjustment syndrome, 395
 trauma, 395-396
 guidelines for work-up and therapy, 395-398
 pathophysiology and pharmacology, 393-394
 Suprascapular nerve injury, 1783-1790
 anatomy, 1783
 clinical signs, 1784-1785
 diagnosis, 1785
 medical management, 1785
 pathogenesis, 1783-1784
 postoperative care, 1788
 prognosis, 1788
 surgery, 1785-1788
 Synovitis, 980-991
 clinical signs, 982-984
 decreased range of motion, 984
 effusion, 982-983
 pain and neurogenic inflammation, 983-984
 definitions, 980-981
 other diagnostic procedures, 989-990
 physical examination, 985-989
 palpation and manipulation, 985-988
 flexion tests, 988-989
 prevalence, 980
 relationship of synovitis and hyaluronic acid, 984-985
 relationship of synovium and articular cartilage, 981-982

EQUINE SUBJECT INDEX—CONTINUED

T

Theriotogenology (see Dystocia, Endometritis)
 Thoracic ultrasonography (see Ultrasonography)

U

Ultrasonography, 1307-1327
 diagnostic ultrasonography, equine thorax,
 1321-1327
 interpreting sonograms, 1322-1326
 performing sonograms, 1322
 echocardiograph examination, basics,
 1312-1320
 color-flow Doppler echocardiography, 1319
 continuous-wave Doppler echocardiography,
 1318-1319
 M-mode echocardiography, 1313-1317
 obtaining the echocardiogram, 1312
 pulsed-wave Doppler echocardiography,
 1317-1320
 two-dimensional real-time examination,
 1312-1313
 equipment selection and use, 1307-1311

common artifacts, 1308
 competence, 1310
 frequency selection, 1308
 greater use of existing equipment, 1310
 machine format, 1308
 probe selection, 1310
 recording, 1308-1310
 selection of equipment for specific needs,
 1310
 special features, 1310
 the ultrasound principle, 1307-1308
 renal ultrasonography, 993-1000
 indications, 994-997
 procedure, 993-994
 Ultrasound (see Ultrasonography)

W

Weakness, caused by hyperkalemic periodic
 paralysis, 83-88
 clinical signs, 83-84, 86
 laboratory evaluation, 84
 treatment, 84-85

FOOD ANIMAL AUTHOR INDEX

B

Bane, D.P., 117
 Berkenkamp, S.D., 740, 881
 Bradford, J.R., 269
 Brown, S.A., 1140
 Bruss, M.L., 1150

C

Campbell, M.E., 285
 Cash, C.W., 1175
 Chalupa, W., 1161
 Constable, P.D., 1008, 1169
 Craig, T.M., 747
 Curtis, S.E., 443

D

Dargatz, D.A., 433, 1347
 Dau, D.J., 117
 Dijkhuizen, A.A., 575
 Drummond, R.O., 740, 881

E

Eastridge, M.L., 1800

F

Friendship, R.M., 755, 889
 Fubini, S.L., 285

G

Galland, J.C., 1150
 Galligan, D.T., 1161
 Gardner, C.E., 277
 Goodger, W.J., 1150

H

Hall, W.F., 755, 889
 Hoffsis, G.F., 274, 1008, 1169, 1794
 Hudson, M.A., 1509

I

Iglesias, J.G., 1341

J

Johnson, J.W., 1175

K

Krabbenborg, R.M.M., 575

L

Lean, I.J., 1150
 Leman, A., 1797
 Linn, J.G., 1499

M

Malone, J.B., 747
 Mercer, H.D., 124
 Merchant, S.R., 1489, 1675
 Miller, G. Y., 1182
 Monfort, J.D., 1182
 Morris, R.S., 575
 Morrow, M., 575

N

Nockels, C.F., 1133

O

Otterby, D.E., 1499

P

Palmer, G.H., 1661
 Pollreis, J.P., 1671
 Polson, D.D., 1509
 Porubcan, R.S., 1353
 Primm, N.D., 755, 889

R

Reinemeyer, C.R., 761
 Richey, E.J., 1661
 Rings, D.M., 1008, 1169
 Roeder, B.L., 1175
 Roussel, A.J., 423

S

Salman, M.D., 433, 1347

T

Troutt, H.F., 1150
 Tubbs, R.C., 105

W

Weaver, L.D., 1150
 Wetzell, T., 1005, 1333
 Whitlock, R.H., 423

VOLUME 12 PAGINATION

<i>Issue</i>	<i>Pages</i>	<i>Issue</i>	<i>Pages</i>
January	98-128	July	1002-1016
February	266-296	August	1128-1200
March	420-448	September	1328-1360
April	572-600	October	1486-1520
May	738-768	November	1658-1688
June	878-896	December	1792-1824

FOOD ANIMAL SUBJECT INDEX

A

Anaplasmosis, bovine, 1661-1669
 diagnosis of acute anaplasmosis, 1662
 immunity and resistance, 1662-1663
 management of anaplasmosis, 1663-1665
 eliminating carrier states, 1663-1664
 handling an anaplasmosis outbreak, 1665
 options for control of anaplasmosis, 1664-1665
 reducing vector transmission, 1663
 pathogenesis, 1661-1662
 transmission, 1661

B

Body condition scores, use in grouping lactating cows, 581-589
 biologic justification, 581-582
 materials and methods, 582-584
 Break-even curves, use of, 1347-1351
 applications, 1348-1350
 break-even curve equations, 1347-1348
 shortcomings of break-even curve analysis, 1350
 assumption of equal values, 1350
 incorporation of risk, 1350

C

Cesarean section, in cattle, 285-291
 complications, 291
 indications, 285-286
 surgical considerations, 286-291
 dorsal recumbency, 287-288
 ventral midline celiotomy, 288
 ventral paramedian celiotomy, 287-288
 ventrolateral left- or right-flank celiotomy, 288-290
 lateral recumbency, 291
 standing right- or left-flank celiotomy, 286-288

Computerized sow replacement, 575-579
 data entry items, 576-577

cost of replacement gifts, 577
 discount rate, 577
 extra cost in case removal, 577
 farrowing efficiency, 576
 feed consumption of sows, 577
 piglet production, 576
 probabilities of removal, 576
 slaughter value of culled sows, 576-577

PorkChop logic, 575-576

results provided, 577-579

financial loss from a delay in conception, 577
 main characteristics of the simulated herd, 577

maximum recommended number of breedings, 579

net benefits of increased life span, 577
 optimum life span of average-producing sows, 577

remaining retained sow life expectancy, 578-579

retention-payoff index of individual sows, 577-578

Cost reduction, assisting clients in, 1797-1799

breeding herd costs, 1797-1798

finishing costs, 1798-1799

nursery costs, 1798

reducing breeding costs, 1799

veterinary checklist for client survival, 1799

D

Decision tree analysis, value to herd health, 433-439

applications, 435-439

computerization, 436-437

definitions and calculations, 434-435

purposes, 433

shortcomings of decision tree analysis, 437

Dermatology (see Zoonotic diseases with cutaneous manifestations)

FOOD ANIMAL SUBJECT INDEX—CONTINUED

- Deworming strategies, swine
 anthelmintics, 889-894
 dichlorvos, 890-891
 fenbendazole, 892-893
 hygromycin B, 890
 ivermectin, 893-894
 levamisole hydrochloride, 891-892
 piperazine, 890
 pyrantel, 891
 thiabendazole, 892
 choosing deworming strategies, 894
 types of endoparasites, 755-759
 Ascaris suum, 755-756
 Hyoststrongylus rubidus, 757-758
 Metastrongylus species, 758
 Oesophagostomum species, 757
 Stephanurus dentatus, 758-759
 Strongyloides ransomi, 758
 Trichuris suis, 756-757
- Diagnostic tests, evaluation and application, 1182-1190
 predictive value of positive test results, 1184-1186
 disease prevalence, 1185
 elimination of paratuberculosis (example), 1185
 validity, 1182-1184
 balancing sensitivity and specificity, 1183-1184
 selecting diagnostic procedures (example), 1184
 sensitivity and specificity (example), 1183
- Diarrhea, chronic, in cattle, 423-431
 causes, 423-428
 abdominal fat necrosis, 425
 bovine virus diarrhea, 425-426
 copper deficiency, 428
 gastrointestinal parasites, 423-424
 Johne's disease (paratuberculosis), 424-425
 other causes, 428
 renal amyloidosis, 428
 salmonellosis, 424-425
 thrombosis of the caudal vena cava, heart failure, and ascites, 425-428
 diagnostic approach, 428-430
 few chronic cases following an acute outbreak, 429
 isolated cases of chronic diarrhea, 429
 many cases of chronic diarrhea, 428-429
 occasional cases of chronic diarrhea, 429
- Drug delivery systems, pasture cattle, 1140-1146
 classic methods of remote drug delivery, 1140-1141
 back rubbers and face flips, 1140-1141
 bands and tail tags, 1141
 dust bags, 1140
 ear tags, 1141
 current innovations, 1141-1142
 continuous-release devices, 1141-1142
 intermittent-release devices, 1142
 slow-release devices, 1141
 future applications, 1142-1145
 implantable infusion pumps, 1143
 subdermal implants, 1144-1145
 iontophoresis, 1146
 ophthalmic drug delivery devices, 1146
 pro-drugs, 1146
 transdermal drug delivery, 1145-1146
 laminated polymeric systems, 1145-1146
 membrane-limited release, 1145
 microreservoir devices, 1145
 monoliths, 1145
 Drug regulations (see Prescription drugs, regulatory issues)
 Drug residue avoidance, dairy cows, 274-275
 National Milk Producers Federation/American Veterinary Medical Association Efforts, 274-275
 Pasteurized Milk Ordinance, 274
 Drug residue avoidance in cattle, 124-126
 attitudes concerning drug residues, 124
 circumstances associated with violative drug residues, 124-125
 clinical approach, 125-126
 existing literature and European drug approvals, 126
 pharmacokinetic drug profile, 125-126
 rapid screening methodology, 126
 risk assessment, 125
 regulatory and consumer concerns, 126
 Dystocia (see Cesarean section)
-
- E** Economies of scale, comparative influence on profitability in six U.S. pig farms, 1509-1519
 materials and methods, 1513-1514
 results and discussion, 1514-1518
 enterprise production budget for a 60-sow farm, 1514-1515
 partial budget comparison of six sizes of pig farms, 1515-1518
 additional management levels, 1516
 breeding stock costs, 1515
 facility and equipment cost, 1515
 feed ingredient costs, 1515
 partial budget summary, 1517-1518
 receipts and income, 1516-1517
 veterinary health services and supplies, 1516
 Environment, effect on welfare and performance of swine, 443-446
 farrowing crates, 444-446
 feeders, 446
 Estrus (see Weaning to estrus)
-
- F** Facilities, effect on welfare and performance of swine, 443-446
 farrowing crates, 444-446
 feeders, 446
 Feed analyses, interpretation of, 1800-1803
 available protein, 1800-1801

FOOD ANIMAL SUBJECT INDEX—CONTINUED

crude protein, 1800
digestible protein, 1801
soluble protein, 1802
undegradable protein, 1801-1802
Feeding problems on dairy farms, approaches
to solving, 1499-1506
feeding methods, 1504-1506
individual grain feeding, 1504-1506
total mixed ration, 1504
feeds, 1499-1501
rations, 1501
body condition scores, 1501
feed intake, 1502-1504
nutrients, 1501-1502

G

Gastrointestinal obstruction in calves, surgical
approaches, 591-599
abomasal disorders, 593-594
abomasal dilatation and volvulus,
593-594
diagnosis, 593-594
treatment, 594
abomasal impaction, 594
diagnosis, 594
treatment, 594
perforating abomasal ulcers, 594
diagnosis, 594
treatment, 594
intestinal disorders, 594-597
atresia, spiral loop of the ascending colon,
596-597
diagnosis, 596
treatment, 596-597
atresia of the rectum or anus, 597
diagnosis, 597
treatment, 597
cecal dilatation and volvulus, 597-598
diagnosis, 597
treatment, 597-598
intestinal volvulus, 597
diagnosis, 597
treatment, 597
intussusception, 594-596
diagnosis, 594
treatment, 594-596
small intestinal obstruction associated with
adhesions or abscesses, 597
clinical evaluation, 591-592
history, 591
laboratory values, 592
physical examination, 591-593
radiography, 592
signalment, 591
surgical management, 592-593
anesthesia, 593
indications for surgery, 592
preoperative preparation, 592-593
selection of the surgical approach, 593
surgical exploration of the abdomen, 593

H

Hypodermosis, bovine
adverse reactions encountered in cattle grub
control, 882-883
organophosphorus intoxication, 882-883
residues in body tissue and milk, 883
teratology, 883
tissue reactions resulting from larval death,
883
Hypoderma bovis, 883
Hypoderma lineatum, 883
control using nonsystemic insecticides, 881
control using systemic insecticides, 881
enzymes of hypoderma, 741
equine furuncular myiasis, 744
furuncular human myiasis, 744
immune response, 741-744
cellular immunity, 742-743
humoral response, 742
hypersensitivity, 743
innate resistance, 742
vaccines, 743-744
intracranial equine myiasis, 744
life cycle, 740-741
ophthalmomyiasis, 744
potential for eradication, 884-885
trim loss and hide devaluation, 884
weight gain performance, 883-884

L

Lactation curves, for dairy cows, 277-282, 295
interpretation of lactation graphs, 279-282
obtaining lactation curves, 277-279
pitfalls of, 282, 295
Lactation performance, suboptimum in sows,
269-273
herd evaluation, 269-270
intrinsic sow factors, 270
management factors, 270-271
building design, 270-271
temperature, 270-271
ventilation, 271
flooring type, 271
sanitation, 271
nutrition, 271-272
treatment and prevention, 272-273
evaluation, 273
herd prevention plan, 272-273
flooring type, 273
genetics, 272
housing, 273
nutrition, 272
sanitation, 273
vaccination and parasite control, 273
ventilation, 272-273
individual sow treatment, 272-273
Liver flukes, 747-754
control based on risk assessment, 751
climate, 751-752
economics, 752
farm habitat, 752

FOOD ANIMAL SUBJECT INDEX—CONTINUED

management, 752
 diagnosis, 750
 fecal examination, 750
 serology, 750
 drug availability, 750-751
 preventive value versus curative value,
 753-754

-
- M** Measures of facility utilization, pigs per crate per
 year, 1005-1007, 1015
 Mineral alterations, association with stress,
 trauma, and infection and the effect on
 immunity, 1133-1139
 effects of mineral deficiency on
 immunocompetence, 1137
 hormonal changes, 1133-1134
 metabolic changes, 1134
 stress and diet, effects on mineral metabolism,
 1134-1137
 calcium, 1135
 copper and zinc, 1136-1137
 magnesium, 1135-1136
 phosphorus, 1135
 potassium, 1134-1135

-
- O** Optimizing feed intake during lactation,
 1333-1339

-
- P** Parasitic gastroenteritis, prevention in dairy
 replacement heifers, 761-766
 autumn considerations, 765
 basic life cycle, 761
 chronology of infection, 762
 environmental requirements, preinfective
 stages, 761-762
 importance of acquired immunity, 765
 parasitic disease, 762
 prevention, 762-763
 strategic control programs, 763
 theoretical control, 762-763
 production responses, 763-765
 seasonal suitability for transmission, 762
 treatment, 762
 Parasitology, bovine (see Hypodermosis, Liver
 flukes, Parasitic gastroenteritis)
 Parasitology, porcine (see Deworming strategies)
 Prescription drugs, regulatory issues, 1794-1795
 Probiotics, 1353-1359
 microorganism specifics, 1353-1354
 minimum effective dose, 1355
 mode of action, 1354
 new gels and pastes, 1354-1355
 probiotic diets, 1356-1358
 probiotic programs, 1355-1356

Pseudorabies virus, swine, 1341-1346
 airborne transmission, 1342-1343
 DNA analysis used for transmission studies,
 1343-1345
 horizontal versus vertical transmission,
 1341-1342
 mechanical transmission, 1342
 perpetuation of infection, 1345-1346

-
- R** Reticulorumen
 motor function of, 1169-1174
 esophageal groove closure, 1172-1173
 rumination, 1171-1172
 secondary contractions, 1169-1171
 vagal indigestion syndrome, 1172-1173
 primary contraction cycle, 1008-1015
 anatomic considerations, 1008
 control of primary contractions, 1009-1010
 extrinsic control of primary contractions,
 1010-1012
 excitatory inputs to the gastric center,
 1010-1011
 inhibitory inputs to the gastric center,
 1011-1012
 hormonal control, 1012
 intrinsic control, 1012
 motility, 1008-1009
 therapy for forestomach hypomotility,
 1012-1013

-
- S** Somatotropin, bovine, 1150-1168
 feeding strategies for treated cows, 1161-1168
 actions of somatotropin, 1161-1162
 effect of nutrition, 1162-1163
 body condition, 1163
 high-energy rations, 1162-1163
 protein, 1163
 ratio of forage to concentrate, 1162
 feeding strategies, 1163-1167
 computer simulation, 1166-1167
 ration concentrations, energy and protein,
 1163-1164
 ration formulation, 1164-1165
 herd implications, 1150-1153
 fertility management, 1152-1153
 herd treatment strategies, 1153
 dose delivery, welfare aspects, 1153
 mammary development, 1153
 therapeutic uses, 1153
 nutrition, 1150-1152
 fats, 1151-1152
 minerals, 1152
 nutrient requirements, 1151
 proteins, 1152
 industry implications, 1153-1157
 dairy industry trends, 1153-1156
 impact on dairy enterprises, 1157

FOOD ANIMAL SUBJECT INDEX—CONTINUED

- impact on veterinary services, 1157
 - increasing milk production in this market, 1156-1157
- Somatotropin, porcine, effects on animal health, 117-121
 - exogenous porcine somatotropin, 118-120
 - disease, 120
 - immune development, 119
 - immune enhancement, 119
 - immune suppression, 119
 - reproduction effects, 120
 - somatotropin and health, 118
 - toxic effects, 119-120
- metabolic effects, 117-118
 - protein metabolism, 117-118
 - carbohydrate and lipid metabolism, 118
- somatotropin secretion, 117
- Sow replacement economics (see Computerized sow replacement)
- Swine reproduction (see Lactation performance)

V

- Vestibular syndrome, 1175-1181
 - case history and presentation, 1175-1176
 - diagnostic considerations, 1176
 - discussion, 1178-1181
 - necropsy findings, 1178
 - treatment, 1176-1178
- Voltage, stray, beef cattle operations, 1671-1673

W

- Weaning-to-estrus interval in sows, 105-115
 - factors influencing, 106-113
 - breed, 112-113
 - environmental factors, 110-112
 - lactation length, 107-108
 - mycotoxins, 113
 - nutrition and feeding management, 106-107
 - pathologic conditions of the reproductive tract, 113
 - season and parity, 109-112
 - suckling pattern, suckling frequency, and litter size, 108-109
- importance of, 105, 106, 113

Z

- Zoonotic diseases with cutaneous manifestations
 - contagious ecthyma, 1493-1496
 - clinical features, 1493
 - clinical management, 1493
 - epidemiology, 1493
 - infections in humans, 1493-1496
 - control of zoonoses, 1496

- dermatophytosis, 1675-1678
 - bovine dermatophytosis, 1676
 - clinical features, 1676
 - clinical management, 1676
 - epidemiology, 1676
 - caprine dermatophytosis, 1676-1677
 - clinical features, 1677
 - clinical management, 1677
 - diagnosis of dermatophytosis in food animals, 1677
 - human dermatophytosis, 1677-1678
 - control of zoonosis, 1678
 - epidemiology, 1675
 - ovine dermatophytosis, 1677
 - porcine dermatophytosis, 1675-1676
 - clinical features, 1675-1676
 - clinical management, 1676
- dermatophilosis, 1678-1680
 - bovine dermatophilosis, 1679
 - clinical features, 1679
 - clinical management, 1679
 - caprine dermatophilosis, 1678-1679
 - clinical features, 1678
 - clinical management, 1678-1679
 - control of zoonoses, 1680
 - diagnosis of dermatophilosis in food animals, 1680
 - epidemiology, 1678
 - human dermatophilosis, 1680
 - ovine dermatophilosis, 1679
 - clinical features, 1679
 - clinical management, 1679
- erysipelas, 1680-1681
 - epidemiology, 1680
 - clinical features, 1680
 - clinical management, 1680
 - diagnosis, 1681
 - erysipelas infection in humans, 1681
- sarcoptic mange, 1489-1491
 - bovine sarcoptic mange, 1490
 - clinical features, 1490
 - clinical management, 1490
 - control of zoonoses, 1491
 - diagnosis, 1491
 - epidemiology, 1489-1490
 - human infestation, 1491
 - ovine and caprine sarcoptic mange, 1490
 - clinical features, 1490
 - clinical management, 1490
 - porcine sarcoptic mange, 1490
 - clinical features, 1490
 - clinical management, 1490
- zoonoses contracted from tick bites, 1491-1493
 - clinical features, 1492
 - control of zoonoses, 1493
 - diagnosis and clinical management, 1492-1493